Explore the Agenda
8:30 am Check In & Registration
Driving ADC Stability & Safety with Next-Generation Conjugation Chemistries
9:00 am Ubi-Tagging: A Ubiquitin-Based Modular Platform for Site-Directed Antibody Conjugation
- Exploiting the highly specific enzymatic ubiquitination machinery for antibody engineering
- Unique feature of iterative conjugation steps
- Ubi-tagged dendritic cell targeted vaccines induce potent T cell activation
9:30 am Protein Conjugation Beyond Maleimide – Exploring Protein Functionalization Using Prenyltransferases
- Prenyltransferases can be used to install a wide variety of biorthogonal functionality in proteins
- That functionality can be used to create protein conjugates for a range of applications ranging from directed cell killing to PET imaging
- Prenyltransferases can also be used to create prenylated nanostructures that can be positioned on the surfaces of cells to transfer a variety of cargos to specific receiver cells
10:00 am Morning Break
Uncovering Innovative Linker & Conjugation Strategies to Overcome Novel Payload Challenges
11:00 am Unlocking Novel Payloads for Antibody-Drug Conjugates Through Targeted Delivery of Hydroxyl-Linked Drugs via ALCO5
- Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Exploring novel conjugation technologies for stable conjugation and traceless release of hydroxy-containing cytotoxins with different intracellular MOAs
- Resulting ADCs are homogenous with a high DAR, have excellent linker stability, and exhibit excellent in vivo PK and efficacy
11:30 am Emerging ADC Designs Provide Opportunity for Differentiated Next Generation ADCs
- The large number of ADCs with tubulin or topoisomerase 1 inhibitor payloads presents a high risk for clinical development of ADCs with these payloads in the future due to overlapping resistance and toxicity
- New payloads with differentiated MOAs will be essential for ADC sequencing in treatment paradigms for patients
- Innovations in linkers and bioconjugation will contribute to reducing the inherent risk in using these new payloads
12:00 pm Lunch
Exploring the Potential of Next-Generation Conjugation Strategies & Site-Specific Technologies
1:00 pm Advancing Site-Specific ADC Conjugation: Skymab’s Next-Generation Platform & First Preclinical Insights
- Innovations in site-specific ADC conjugation – overcoming the limitations of traditional maleimide chemistry
- Skymab’s novel platform – enhancing stability, DAR control, and therapeutic index through optimized linker strategies
- Preclinical results and future directions – first insights into Skymab’s lead ADC candidate and its potential clinical impact
1:30 pm Unlocking the ADC Toolbox: Stable Chemistry & Sites of Conjugation Combine to Improve Therapeutic Index
- Stable conjugation chemistry and site of conjugation impact the stability of conjugates
- Long PKs increase tumor exposure and improve efficacy of ADC
- A move away from unstable thiol-maleimide conjugation chemistry and exposed conjugation sites will enable development of novel ADCs with improved therapeutic indices
2:00 pm Afternoon Break
Unlocking New Therapeutic Potential & Expanding Beyond Traditional Payloads Through Linker Innovations
2:30 pm Linker & Conjugation Based Strategies for Improving MMAE-Based ADCs
- Optimization of MMAE-based ADCs through linker composition
- Improving payload properties
- Identifying the ideal conjugation site
3:00 pm A Linker Platform For Antibody Drug Conjugates: Expanding The Therapeutic Window
- Baylink's novel linkers enable use of hydrophobic drugs at high DAR, and can reduce off-target effects
- It expands the diversity of payloads, including chemotherapy, protein degraders, and immunotherapy
- The lead candidate will enter phase I clinical trial in 2026